| Autor: |
Satyatanusha, S., Percy, J., Rao, P. Srinivasa, Vijayalakshmi, U. B., Prabodh, V. Siva |
| Předmět: |
|
| Zdroj: |
European Journal of Cardiovascular Medicine; 2024, Vol. 14 Issue 3, p991-999, 9p |
| Abstrakt: |
Introduction: Depression is common in patients with diabetes and it is known to be twice as frequent in patients with diabetes, as in the general population. Metformin, an anti-diabetic agent is commonly used in type 2 diabetes mellitus as a first line drug and long-term metformin treatment is a known pharmacological cause of vitamin B12 deficiency. Low serum B12 status in the general population is associated with a significant risk of depressive symptoms. Metformin has also been known to enhance antidepressant efficacy and improve cognition in preclinical studies. Objective: The aim of this study was to determine the association of metformin usage, serum vitamin B12 and depression in patients with type 2 diabetes. Methods: This cross sectional study was carried out from September 1st 2022 to October 31st 2022. Sociodemographic data was collected. Serum B12 was estimated and depression was diagnosed based on the Patient Health Questinnaire-9. Results: there was a strong negative correlation between serum B12 status and depression as assessed by PHQ-9 p≤0.000005. There was a moderate negative correlation between metformin dosage and serum B12 status p≤0.01. Conclusion: This study shows a significant negative relation between vitamin B12 and Patient Health Questionnaire-9 scores which indicate that lower the vitamin B12 value, higher is the PHQ-9 score that implies severity of depression. Similarly a negative correlation was observed between metformin dosage and serum vitamin B12 that implies larger doses of metformin tend to decrease the serum vitamin B12 levels. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
